Nobilis IB H120

국가: 영국

언어: 영어

출처: VMD (Veterinary Medicines Directorate)

유효 성분:

Infectious bronchitis virus

제공처:

Intervet UK Ltd

ATC 코드:

QI01AD07

INN (국제 이름):

Infectious bronchitis virus

승인 상태:

Expired

제품 특성 요약

R
EVISED
26 M
AY
2010
AN. 1679/2009
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobilis IB H120
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION OF PRODUCT
Active ingredient:
per dose
Live Avian Infectious Bronchitis virus strain IB H120
≥ 3.0 log
10
EID
50
For a fulllist of excipients, see 6.1
3.
PHARMACEUTICAL FORM
Lyophilisate for suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES:
Chickens
4.2
INDICATIONS FOR USE SPECIFYING THE TARGET SPECIES
For the active primary immunisation of chickens from day-old, to
reduce mortality and
clinical signs resulting from infection with Infectious Bronchitis of
the Massachusetts
serotype.
Onset of immunity:
at latest 3 weeks (based upon vaccination-challenge interval tested;
this
period may be shorter but this has not been investigated)
Duration of immunity: at least 6 weeks
4.3
CONTRA-INDICATIONS
Do not vaccinate unhealthy birds. Sick or weak birds will not develop
adequate immunity
following vaccination.
4.4
SPECIAL WARNINGS FOR TARGET SPECIES:
The vaccine virus may spread to unvaccinated birds. Primary
vaccination of fully susceptible
laying hens with Nobilis IB H120 might cause a slight fall in egg
production. (see also section
4.7)
4.5
SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN
BY THE
PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS.
4.5.1
Special precautions for use in animals
In young birds the intensity of the reaction produced by the vaccine
and also the degree of
immunity will vary. This variation is related to the presence and
amount of maternal
antibodies to IB in the chicken and also the general health and
condition of the birds. Thus,
hygiene and management are particularly important in the
post-vaccination period.
Antibiotic medication: When stocks are known to be infected with
mycoplasma or there is a
history of other infections, e.g. E. coli, it is suggested that
antibiotics are administered to
reduce the level of infection. The antibiotic manufacturers'
recommendations should be
followed at